Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.

CEO

Belén Garijo López

CEOBelén Garijo López

Employees

76,493

Employees76,493

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1994

Founded1994

Employees

76,493

Employees76,493

SNY Key Statistics

Market cap

106.50B

Market cap106.50B

Price-Earnings ratio

18.41

Price-Earnings ratio18.41

Dividend yield

3.61%

Dividend yield3.61%

Average volume

2.38M

Average volume2.38M

High today

$44.33

High today$44.33

Low today

$43.64

Low today$43.64

Open price

$44.02

Open price$44.02

Volume

2.38M

Volume2.38M

52 Week high

$52.68

52 Week high$52.68

52 Week low

$42.33

52 Week low$42.33

SNY News

TipRanks 5h

Sanofi’s New STRIDE Registry: Tracking Real-World COPD Outcomes for Dupilumab

Sanofi SA (SNY) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings an...

TipRanks 5h

Sanofi’s SAR442257 Trial Update: Early Oncology Progress With Measured Investor Upside

Sanofi (SNYNF) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and...

TipRanks 1d

Sanofi announces FDA grants priority review to venglustat new drug application

The FDA has granted priority review to Sanofi’s (SNY) new drug application for venglustat, an investigational oral glucosylceramide synthase inhibitor, for the...

Analyst ratings

57%

of 7 ratings

Buy

42.9%

Hold

57.1%

Sell

More SNY News

Fortune 2d

Sanofi is building its own AI ecosystem to give the French pharma giant an edge - Fortune

...

TipRanks 2d

Sanofi’s Efdoralprin Alfa Shows Phase 2 Superiority Over Standard AATD Therapy

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Simply Wall St 7d

Assessing Novavax Valuation As Shah Capital Challenges Leadership And Sanofi Partnership

Advertisement Activist pressure puts Novavax (NVAX) leadership under scrutiny Shah Capital Management has challenged Novavax (NVAX) leadership in a detailed E...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.